Jefferies Reiterates Buy Rating on Amgen (AMGN) As O.M. Phase III Data Heart Failure Data Comes Soon
Tweet Send to a Friend
Jefferies’ analyst Michael Yee continues to like Amgen (NASDAQ: AMGN) overall and especially for the next year. He maintains a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
